A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19.
COVID-19
Case-control study
Comorbidities
Deprivation
Ethnicity
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
15
10
2020
medline:
15
10
2020
entrez:
14
10
2020
Statut:
ppublish
Résumé
People of minority ethnic backgrounds may be disproportionately affected by severe COVID-19. Whether this relates to increased infection risk, more severe disease progression, or worse in-hospital survival is unknown. The contribution of comorbidities or socioeconomic deprivation to ethnic patterning of outcomes is also unclear. We conducted a case-control and a cohort study in an inner city primary and secondary care setting to examine whether ethnic background affects the risk of hospital admission with severe COVID-19 and/or in-hospital mortality. Inner city adult residents admitted to hospital with confirmed COVID-19 ( The 872 cases comprised 48.1% Black, 33.7% White, 12.6% Mixed/Other and 5.6% Asian patients. In conditional logistic regression analyses, Black and Mixed/Other ethnicity were associated with higher admission risk than white (OR 3.12 [95% CI 2.63-3.71] and 2.97 [2.30-3.85] respectively). Adjustment for comorbidities and deprivation modestly attenuated the association (OR 2.24 [1.83-2.74] for Black, 2.70 [2.03-3.59] for Mixed/Other). Asian ethnicity was not associated with higher admission risk (adjusted OR 1.01 [0.70-1.46]). In the cohort study of 1827 patients, 455 (28.9%) died over a median (IQR) of 8 (4-16) days. Age and male sex, but not Black (adjusted HR 1.06 [0.82-1.37]) or Mixed/Other ethnicity (adjusted HR 0.72 [0.47-1.10]), were associated with in-hospital mortality. Asian ethnicity was associated with higher in-hospital mortality but with a large confidence interval (adjusted HR 1.71 [1.15-2.56]). Black and Mixed ethnicity are independently associated with greater admission risk with COVID-19 and may be risk factors for development of severe disease, but do not affect in-hospital mortality risk. Comorbidities and socioeconomic factors only partly account for this and additional ethnicity-related factors may play a large role. The impact of COVID-19 may be different in Asians. British Heart Foundation; the National Institute for Health Research; Health Data Research UK.
Sections du résumé
BACKGROUND
BACKGROUND
People of minority ethnic backgrounds may be disproportionately affected by severe COVID-19. Whether this relates to increased infection risk, more severe disease progression, or worse in-hospital survival is unknown. The contribution of comorbidities or socioeconomic deprivation to ethnic patterning of outcomes is also unclear.
METHODS
METHODS
We conducted a case-control and a cohort study in an inner city primary and secondary care setting to examine whether ethnic background affects the risk of hospital admission with severe COVID-19 and/or in-hospital mortality. Inner city adult residents admitted to hospital with confirmed COVID-19 (
FINDINGS
RESULTS
The 872 cases comprised 48.1% Black, 33.7% White, 12.6% Mixed/Other and 5.6% Asian patients. In conditional logistic regression analyses, Black and Mixed/Other ethnicity were associated with higher admission risk than white (OR 3.12 [95% CI 2.63-3.71] and 2.97 [2.30-3.85] respectively). Adjustment for comorbidities and deprivation modestly attenuated the association (OR 2.24 [1.83-2.74] for Black, 2.70 [2.03-3.59] for Mixed/Other). Asian ethnicity was not associated with higher admission risk (adjusted OR 1.01 [0.70-1.46]). In the cohort study of 1827 patients, 455 (28.9%) died over a median (IQR) of 8 (4-16) days. Age and male sex, but not Black (adjusted HR 1.06 [0.82-1.37]) or Mixed/Other ethnicity (adjusted HR 0.72 [0.47-1.10]), were associated with in-hospital mortality. Asian ethnicity was associated with higher in-hospital mortality but with a large confidence interval (adjusted HR 1.71 [1.15-2.56]).
INTERPRETATION
CONCLUSIONS
Black and Mixed ethnicity are independently associated with greater admission risk with COVID-19 and may be risk factors for development of severe disease, but do not affect in-hospital mortality risk. Comorbidities and socioeconomic factors only partly account for this and additional ethnicity-related factors may play a large role. The impact of COVID-19 may be different in Asians.
FUNDING
BACKGROUND
British Heart Foundation; the National Institute for Health Research; Health Data Research UK.
Identifiants
pubmed: 33052324
doi: 10.1016/j.eclinm.2020.100574
pii: S2589-5370(20)30318-7
pmc: PMC7545271
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100574Subventions
Organisme : Medical Research Council
ID : MC_PC_17214
Pays : United Kingdom
Organisme : Department of Health
ID : RP-PG-0407-10314
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501633/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K006584/1
Pays : United Kingdom
Organisme : Alzheimer's Society
ID : 171
Pays : United Kingdom
Organisme : Department of Health
ID : 05/40/04
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13041
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0902393
Pays : United Kingdom
Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
JTHT received research funding from Innovate UK & Office of Life Sciences, and iRhythm Technologies, and holds shares <£5000 in Glaxo Smithkline and Biogen. The other authors declare no competing interests.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
PLoS One. 2019 Nov 25;14(11):e0225625
pubmed: 31765395
Am J Public Health. 2000 Nov;90(11):1694-8
pubmed: 11076232
EClinicalMedicine. 2020 Sep;26:100513
pubmed: 32838245
Int J Epidemiol. 2012 Feb;41(1):33-42
pubmed: 21044979
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
JAMA. 2020 Jun 23;323(24):2466-2467
pubmed: 32391864
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Lancet. 2020 May 30;395(10238):1705-1714
pubmed: 32416785
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Cell. 2016 Oct 20;167(3):657-669.e21
pubmed: 27768889
J Am Coll Cardiol. 2013 Apr 30;61(17):1777-86
pubmed: 23500273
Stat Med. 1999 Mar 30;18(6):681-94
pubmed: 10204197
EClinicalMedicine. 2020 Jun 03;23:100404
pubmed: 32632416
BMC Med Inform Decis Mak. 2018 Jun 25;18(1):47
pubmed: 29941004
Cancer Treat Res. 1995;75:95-112
pubmed: 7640169
Trends Immunol. 2019 Dec;40(12):1105-1119
pubmed: 31786023
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
JAMA. 2000 May 3;283(17):2253-9
pubmed: 10807384
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
JAMA. 2020 Jun 2;323(21):2192-2195
pubmed: 32347898
EClinicalMedicine. 2020 Aug;25:100466
pubmed: 32840492
Lancet Infect Dis. 2020 Sep;20(9):1034-1042
pubmed: 32422204
JAMA Intern Med. 2020 Aug 17;:
pubmed: 32804192
Diabetes Res Clin Pract. 2020 Jan;159:107984
pubmed: 31846667
Lancet. 2020 May 2;395(10234):1421-1422
pubmed: 32330427
Eur J Heart Fail. 2020 Jun;22(6):967-974
pubmed: 32485082